Skip to main content

Table 2 Univariate and multivariate analysis of overall survival and disease-free survival in the whole cohort

From: Exploring the clinical value of preoperative serum gamma-glutamyl transferase levels in the management of patients with hepatocellular carcinoma receiving postoperative adjuvant transarterial chemoembolization

Characteristics OS DFS
Univariate Multivariate Univariate Multivariate
HR (95CI) P-value HR (95CI) P-value HR (95CI) P-value HR (95CI) P-value
Age (years) 1.00 (0.99–1.01) 0.818    1.00 (0.99–1.01) 0.852   
Sex (Male vs Female) 0.95 (0.77–1.16) 0.611    0.99 (0.84–1.18) 0.950   
HBV infection (Yes vs No) 1.01 (0.80–1.28) 0.908    1.13 (0.93–1.38) 0.208   
Cirrhosis (Yes vs No) 0.95 (0.81–1.11) 0.498    1.08 (0.95–1.24) 0.237   
TBil (μmol/L) 1.02 (1.01–1.03) 0.003 1.01 (1.00–1.02) 0.087 1.01 (1.00–1.02) 0.010 1.01 (1.00–1.02) 0.186
Child-pugh (B vs A) 2.04 (1.54–2.70) < 0.001 1.27 (0.93–1.72) 0.131 1.72 (1.34–2.20) < 0.001 1.13 (0.86–1.49) 0.371
AFP (> 400 vs 400 ng/mL) 1.66 (1.43–1.94) < 0.001 1.43 (1.22–1.67) < 0.001 1.35 (1.19–1.54) < 0.001 1.22 (1.07–1.40) 0.004
γ-GT (> 54 vs ≤54 U/L) 1.76 (1.51–2.05) < 0.001 1.38 (1.17–1.62) < 0.001 1.69 (1.49–1.92) < 0.001 1.42 (1.24–1.63) < 0.001
Transfusion (Yes vs No) 2.01 (1.54–2.61) < 0.001 0.89 (0.66–1.22) 0.479 1.97 (1.57–2.48) < 0.001 1.12 (0.86–1.46) 0.391
Tumor number (Multiple vs Single) 1.83 (1.54–2.17) < 0.001 1.50 (1.23–1.82) < 0.001 1.82 (1.58–2.10) < 0.001 1.53 (1.29–1.80) < 0.001
Tumor diameter (cm) 1.11 (1.09–1.13) < 0.001 1.07 (1.05–1.09) < 0.001 1.08 (1.06–1.09) < 0.001 1.04 (1.02–1.06) < 0.001
ES grading (III/IV vs I/II) 1.80 (1.34–2.42) < 0.001 1.28 (0.95–1.74) 0.108 1.42 (1.13–1.78) 0.003 1.08 (0.85–1.37) 0.528
Capsule (Absent vs Present) 1.42 (1.20–1.70) < 0.001 1.35 (1.12–1.62) 0.001 1.26 (1.09–1.47) 0.002 1.16 (0.99–1.35) 0.064
Satellite (Yes vs No) 1.51 (1.30–1.75) < 0.001 0.98 (0.81–1.18) 0.812 1.46 (1.29–1.66) < 0.001 1.05 (0.90–1.22) 0.527
MVI (Absent vs Present) 1.92 (1.65–2.23) < 0.001 1.51 (1.27–1.79) < 0.001 1.68 (1.48–1.90) < 0.001 1.40 (1.22–1.62) < 0.001
PA-TACE (Yes vs No) 0.89 (0.75–1.05) 0.165    0.93 (0.81–1.06) 0.280   
  1. Note: OS overall survival; DFS disease-free survival; HR hazard ratio; CI confidence interval; HBV hepatitis B virus, TBil total bilirubin; AFP alpha-fetoprotein; γ-GT gamma-glutamyl transferase; ES Edmondson-Steiner; MVI microvascular invasion; PA-TACE postoperative adjuvant transarterial chemoembolization
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us